

Workshop: Progress and Advances in Preclinical immuno-Oncology Research

SMOC's Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

The rise of cancer immunotherapy such as immune checkpoint modulators, bispecific antibodies, T cell therapy and personalized cancer vaccines instigated a wide range of unique preclinical and translational challenges. The demand for preclinical models and approaches to minimize translational failures in immuno-oncology is at an all-time high. The need for leveraging phenotypic features of models, for rational design of combination therapies, and for researching the cancer-immune cell interactions add to the complexity of translational research in immuno-oncology. SMOC's Annual **Progress and Advances in Preclinical immuno-Oncology Research**: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Final Agenda

1:00-4:35pm BJT

December 17, 2020

Bibo hall, Parkyard Hotel

699 Bibo Road, Zhang Jiang High Tech Park Pudong, Shanghai

Time	Topic	Speaker(s) and Affiliation
1:00-1:30 pm	Registration	
1:30-1:40 pm	Opening speech	
1:40-2:20 pm	Exploration and Development of Next Generation Tumor Immunotherapy Antibody	Wenzhi Tian , MD, Chairman & CEO of ImmuneOnco Biopharma Co., Ltd
2:20-3:00 pm	Animal modeling for immuno-oncology drug discovery	Davy Ouyang , Vice President of Scientific Research & Innovation at Crown Bioscience Inc
3:00-3:15 pm	Coffee break	
3:15-3:55 pm	Immuno-Oncology Therapies & Humanized Animal Models	Jia Zeng , R & D Project Leader of ALLCELLS

3:55-4:35 pm	Genetically engineered mouse models in oncology research and cancer medicine	Haiyan Zhu , Director of Industrial Customer Department at Shanghai Model Organisms Center, Inc.
--------------	---	---